CoChat

Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada

Caro, J. J., Getsios, D., Caro, I., Klittich, W. S., O'Brien, J. A. · 2004 · Diabetic Medicine
Cited by 67

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aims To compare the health and economic outcomes of using acarbose, an intensive lifestyle modification programme, metformin or no intervention to prevent progression to diabetes in Canadian individuals with impaired glucose tolerance (IGT). Methods A model was developed to simulate the course of individuals with IGT under each treatment strategy. Patients remain in the IGT state or transition from IGT to diabetes, to normal glucose tolerance (NGT) or to death. Effectiveness and resource use data were derived from published intervention trials. A comprehensive health‐care payer perspective incorporating all major direct costs, reported in 2000 Canadian dollars, was adopted. Results Over a decade, 70 of the 1000 untreated patients are expected to die and 542 develop diabetes. Intensive lifestyle modification is estimated to prevent 117 cases of diabetes, while metformin would prevent 52 and acarbose 74 cases. The proportion of those who return to NGT also increases with any treatment. While lifestyle modification is more effective, it can increase overall costs depending on how it is implemented, whereas acarbose and metformin reduce costs by nearly $1000 per patient. Lifestyle modification was cost effective, varying from $749/life year gained (LYG) vs. no treatment to about $10 000/LYG vs. acarbose. Acarbose costs somewhat more than metformin, but is more effective: $1798/LYG. Conclusion The results of this model suggest that the treatment of IGT in Canada is a cost‐effective way to prevent diabetes and may generate savings. While pharmacological treatments tended to be less costly, intensive lifestyle modification, if maintained, led to the greatest health benefits at reasonable incremental costs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2004.01330.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 67

Metadata

Authors
Caro, J. J., Getsios, D., Caro, I., Klittich, W. S., & O'Brien, J. A.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2004-10-20
Volume
21
Issue
11
Pages
1229-1236
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2138452846
Cited by
67
References
7
FWCI
9.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada. https://app.cochat.ai/papers/10.1111/j.1464-5491.2004.01330.x
The paper
Caro, J. J., Getsios, D., Caro, I., Klittich, W. S., & O'Brien, J. A. (2004). Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2004.01330.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.